Eli Lilly and Company CEDEAR (LLY)
BCBA
34,220.00
+880.00 (+2.64%)
Closed
Oct 7, 2026
Day's Range
33,940.0034,680.00
52 wk Range
19,640.0036,520.00
Financial Statements - LLY - Eli Lilly and Company CEDEAR
Revenue
65.17B▼ 99.9%
Net Income
20.64B▼ 99.9%Net Margin 31.7%
EBITDA
35.08B▼ 99.9%
Free Cash Flow
5.96B▼ 99.0%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 65.17B | 65.21T | 34.12B | 28.54B | 28.31B | 24.53B |
| Cost of Goods | 11.05B | 12.18T | 7.08B | 6.62B | 7.31B | 5.48B |
| Gross Profit | 54.12B | 53.02T | 27.04B | 21.91B | 21B | 19.05B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 29.69B | 24.66T | 10.78B | 8.65B | 7.93B | 7.10B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -3.96B | -5.43T | -3.92B | -1.57B | -1.46B | 455.10M |
| Pre Tax Income | 25.73B | 18.35T | 6.55B | 6.80B | 6.15B | 7.22B |
| Income Tax | 5.09B | 3.02T | 1.31B | 561.60M | 573.80M | 1.03B |
| Net Income | 20.64B | 15.33T | 5.24B | 6.24B | 5.58B | 6.19B |
| EPS Basic | 92.266428 | 47.195773 | 23.306748 | 26.288858 | 23.41187 | 25.899079 |
| EPS Diluted | 91.8 | 46.84 | 23.2 | 26.288858 | 23.41187 | 25.899079 |
| Basic Shares Outstanding | 223.70M | 324.85B | 212.47K | 224.94K | 225.76K | 226.46K |
| Diluted Shares Outstanding | 223.70M | 324.85B | 212.47K | 224.94K | 225.76K | 226.46K |
| Ebit | 29.69B | 19.48T | 7.04B | 7.13B | 6.49B | 7.58B |
| Ebitda | 35.08B | 28.11T | 12.45B | 10.22B | 9.55B | 8.26B |
| Net Income Continuous Operations | 20.64B | 15.33T | 5.24B | 6.24B | 5.58B | 6.19B |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
